terazosin has been researched along with nifedipine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Sen, S; Sinha, N | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Divish, B; Langenstroer, P; Lepor, H; Opgenorth, T; Shapiro, E; Tang, R | 1 |
| Chiba, T; Fukutomi, J; Hattori, K; Maruyama, K; Nagatomo, T; Takeda, M; Yamaguchi, M | 1 |
| Abe, I; Fujishima, M; Hasuo, Y; Nishino, Y; Onaka, U; Setoguchi, M | 1 |
| Buzuyeva, II; Filyushina, EE; Lazarev, VA; Markel', AL; Shmerling, MD; Yakobson, GS | 1 |
| Ong, CT; Sung, SF; Tong, SH; Wu, CS | 1 |
| Chen, YT; He, Q; Li, H; Liao, BH; Liu, QY; Wang, KJ; Yang, TX | 1 |
| Ju, M; Qu, J; Wu, W; Yu, X; Zheng, J | 1 |
2 review(s) available for terazosin and nifedipine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A network meta-analysis on the beneficial effect of medical expulsive therapy after extracorporeal shock wave lithotripsy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Calcium Channel Blockers; Combined Modality Therapy; Humans; Kidney Calculi; Lithotripsy; Network Meta-Analysis; Nifedipine; Prazosin; Sulfonamides; Terpenes; Treatment Outcome; Ureteral Calculi; Urinary Calculi | 2017 |
2 trial(s) available for terazosin and nifedipine
| Article | Year |
|---|---|
Comparative efficacies of a calcium antagonist and an alpha1 blocker in elderly hypertensive patients with stroke.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Aging; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cerebrovascular Disorders; Circadian Rhythm; Cross-Over Studies; Female; Hemodynamics; Humans; Hypertension; Male; Nifedipine; Prazosin; Quality of Life | 1998 |
Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Lithotripsy; Male; Nifedipine; Pain Measurement; Postoperative Complications; Prazosin; Quality of Life; Time Factors; Treatment Outcome; Ureteral Calculi; Ureteroscopy; Urethra | 2020 |
13 other study(ies) available for terazosin and nifedipine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies.
Topics: Adrenergic alpha-Antagonists; Calcium; Dose-Response Relationship, Drug; Endothelins; Epithelium; Humans; Immunohistochemistry; In Vitro Techniques; Indomethacin; Isometric Contraction; Male; Muscle, Smooth; Nifedipine; Prazosin; Prostate | 1993 |
Two district alpha(1)-adrenoceptor subtypes in the human prostate: assessment by radioligand binding assay using 3H-prazosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Binding, Competitive; Dioxanes; Humans; In Vitro Techniques; Kinetics; Male; Nifedipine; Phentolamine; Piperazines; Prazosin; Prostate; Protein Binding; Radioligand Assay; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Tritium | 1996 |
Delayed effects of hypotensive drugs on structural characteristics of the renal glomerular system in hypertensive NISAG rats.
Topics: Animals; Antihypertensive Agents; Enalapril; Hypertension; Kidney Glomerulus; Losartan; Male; Nifedipine; Prazosin; Rats; Time Factors | 2007 |
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Calcium Channel Blockers; Cerebral Infarction; Diabetes Mellitus, Type 2; Diffusion Magnetic Resonance Imaging; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Famotidine; Humans; Hypertension; Hypoglycemic Agents; Labetalol; Male; Metformin; Middle Aged; Nifedipine; Peptic Ulcer; Prazosin; Sulfonylurea Compounds | 2012 |